This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

24/7 Access
Digital & In-Person

What is mRNA?

Messenger RNA (mRNA) is a large family of RNA molecules that convey genetic information from DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression. 

A new class of therapeutics based on mRNA called mRNA therapeutics is currently being explored by a number of companies.

Featured mRNA Sessions at TIDES US

May 20-23, 2019 in San Diego, CA

mRNA as a Platform Technology Ideally Suited for Individualized Therapeutics

Andreas Kuhn, PhD
Vice President, RNA Biochemistry & Manufacturing
BioNTech RNA Pharmaceuticals GmbH

Overcoming the Hurdle of Subcutaneous Delivery of mRNA in LNP to Enable Treatment of Chronic Diseases

Shalini Andersson, PhD
Senior Director, Drug Metabolism & Pharmacokinetics

Characterization of Critical Quality Attributes of mRNA, A Novel Therapeutic Modality

Huijuan Li, PhD
Head, Analytical Development
Moderna Therapeutics

Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs – A Novel Approach with Broad Therapeutic Potential

Anthony Partridge, PhD
Principal Scientist, Early Discovery Pharmacology
Merck, Sharp & Dohme

Evaluation of Modified Interferon alpha mRNA Constructs for the Treatment of Non-melanoma Skin Cancer

Markus Mandler, PhD
Accanis Biotech

Messenger RNA Therapeutics for Bone Regeneration and for Pulmonary Diseases

Christian Plank, PhD
Chief Technology Officer
Ethris GmbH

Novel mRNA Immunotherapies

Robert Jabulowsky, PhD
Deputy Head of Project Management
BioNtech AG

Nucleoside-modified mRNA Immunization against Infectious Diseases

Nobert Pardi, PhD
Research Assistant Professor of Medicine
University of Pennslyvania

mRNA Based Vaccines Expressing RSV are Immunogenic and Protective in Preclinical Models of Respiratory Syncytial Virus Infection

Andrew Geall, PhD
Vice President of Formulations, Analytics, and Chemistry
Avidity Biosciences